Symposia

Future Leaders Special Symposium

Targeting SPINK1 in ETS negative prostate cancer
Scott A. Tomlins, University of Michigan, Ann Arbor, MI

Molecular imaging of carbon metabolism in tumors using MRI
Ferdia A. Gallagher, Cambridge Research Institute, Cambridge, United Kingdom

RNA localization by APC: A new role for an old tumor-suppressor
Stavroula Mili, University of Virginia School of Medicine, Charlottesville, VA

TGF-β signaling, intestinal homeostasis, and cancer: Novel insights through stochastic gene alterations
Ashleigh J. Miller, Oregon Health and Science University, Portland, OR

Cancer Systems Biology

Systemic approaches to oncogenic networks and to pharmaceutical perturbations: The HER/ErbB example
Yosef Yarden, Weizmann Institute of Science, Rehovot, Israel

Biological insights from quantitative analysis of oncogenic ErbB signaling networks
Forest M. White, Massachusetts Institute of Technology, Cambridge, MA

Profiling the breast tumor microenvironment
Morag Park, McGill University Goodman Cancer Centre, Montréal, QC, Canada

Multipathway modeling of network dysregulation in hepatocellular carcinoma
Douglas A. Lauffenburger

DNA Damage Response: From Checkpoints to Repair

Complex biological responses to DNA damage agents
Leona D. Samson, Massachusetts Institute of Technology, Cambridge, MA

New insights into the ATM-p53 pathway
Michael B. Kastan, St. Jude Children’s Research Hospital, Memphis, TN

Ubiquitin recognition and turnover in BRCA1-dependent DNA repair and tumor suppression
Roger A. Greenberg, University of Pennsylvania School of Medicine, Philadelphia, PA

Cell cycle and checkpoint control
Helen M. Piwnica-Worms

Metastasis Models, Microenvironment, and Mechanisms

Mediators of metastasis
Joan Massagué

The role of the microenvironment in breast cancer progression
Kornelia Polyak, Dana-Farber Cancer Institute, Boston, MA

Cancer cell dissemination
Tyler Jacks, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA

The metastatic phenotype
Robert A. Weinberg, Whitehead Institute for Biomedical Research, Cambridge, MA

MicroRNAs and Human Cancer

Role of microRNAs in human cancer
Carlo M. Croce

Inflammation and cancer: Microenvironment, cytokines, microRNA, and p53
Curtis C. Harris, National Cancer Institute, Bethesda, MD

MicroRNAs as novel diagnostic and therapeutic tools in cancer
Frank Slack, Yale University, New Haven, CT

Targeting of microRNAs for therapeutics
Sakari Kauppinen, University of Copenhagen, Copenhagen, Denmark

Regulation of Angiogenesis by Microenvironmental Cues

Introduction
Gabriele I. A. Bergers

Growth factor cues for angiogenic sprouting and vascular network formation
Kari K. Alitalo, University of Helsinki, Helsinki, Finland

A role for VEGF as a negative regulator of pericyte function and vessel maturation: Important implications for cancer therapy
David A. Cheresh, Moores UCSD Cancer Center, La Jolla, CA

Remodeling tumor vasculature: A new approach to therapy
Ruth A. Ganss, Western Australia Institute for Medical Research, Perth, Australia

Contribution of neo-angiogenesis to stem cell regeneration
Shahin Rafii, Cornell University Medical College, New York, NY

Resistance to Targeted Therapies

Lessons from chemotherapy and reversal of multidrug resistance
Branimir I. Sikic

Resistance to hormonal therapies
Angela M. H. Brodie, University of Maryland School of Medicine, Baltimore, MD

Drug resistance via mutations in target genes
William Pao, Memorial Sloan-Kettering Cancer Center, New York, NY

Activation of alternative pathways as a mechanism of resistance to targeted therapies
Jeffrey A. Engelman, Massachusetts General Hospital, Boston, MA

Transcription and Histone Modification in Cancer

Analysis of Drosophila protein complexes that modify chromatin
Jerry L. Workman, Stowers Institute for Medical Research, Kansas City, MO

Chromatin modifications of human enhancers reflect global cell type species gene expression
Bing Ren, University of California, San Diego, La Jolla, CA

Epigenetic regulation of aging and cancer
Jessica K. Tyler, University of Colorado Health Sciences Center, Denver, CO

E2F1 represses beta-cateninin-dependent transcription, and its activity is antagonized by pRB and cdk8
Nicholas Dyson, Massachusetts General Hospital, Charlestown, MA

Ethical Issues in Publications

Ethical issues in publication: What are the boundaries and whose responsibility is it?
Vincent H. L. Lee, The Chinese University of Hong Kong, Shatin, N. T., Hong Kong SAR, China

Ethical issues in publications: What should journal Editorial Boards do and not do
Yves A. De Clerck, Children’s Hospital Los Angeles, Los Angeles, CA

Assuring the validity of preclinical and clinical data for publication
Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA

When is “conflict of interest” really a conflict?
Stephen A. Cannistra, Beth Israel Deaconess Medical Center, Boston, MA

Circulating Tumor Cells: Biology and Clinical Applications for Research and Practice

Biological properties of disseminating tumor cells in cancer patients
Klaus Pantel, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Microfluidic detection and analysis of circulating tumor cells
Shyamala Maheswaran, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA

Circulating tumor cells in drug development: Lessons from trials with abiraterone
Johann S. de Bono, Royal Marsden Hospital, Sutton, United Kingdom

Qualification of circulating tumor cells as a biomarker: Generating evidence for an intended use
Howard I. Scher

Cancer Genomics and Drug Discovery

Functional genomics to identify and validate cancer targets
William C. Hahn, Dana-Farber Cancer Institute, Boston, MA

Gene expression-based approaches to small molecule discovery for cancer
Kimberly Stegmaier, Dana-Farber Cancer Institute, Boston, MA

Towards functional annotation of the cancer genome
Michael A. White, University of Texas Southwestern Medical Center, Dallas, TX

Finding mechanisms of drug resistance using functional genetic screens
René Bernards

Epithelial-Mesenchymal Transitions in Cancer

Snail regulation and EMT
Greg D. Longmore

Pathways regulating basement membrane transmigration in EMT
Stephen J. Weiss, University of Michigan, Ann Arbor, MI

Inactivation of failsafe programs by Twist oncoproteins in EMT
Alain Puisieux, Centre Léon-Bérard, Lyon, France

De novo epigenetic remodeling and EMT in epithelial cells
Thea D. Tlsty

How Do Mouse Models of Cancer Inform Clinical Trials?

Use of murine models to validate and test drug targets in myeloproliferative diseases
D. Gary Gilliland, Harvard Medical School, Boston, MA

Pharmacological therapy of mouse models of thyroid cancer induced by oncogenic effectors in the MAPK and PI3K pathways
James A. Fagin, Memorial Sloan-Kettering Cancer Center, New York, NY

Targeting the cancer stem cell for therapy and the co-clinical trial project
Pier Paolo Pandolfi, Beth Israel Deaconess Medical Center, Boston, MA

Genetically engineered mouse models for neuroblastoma: Applications to developmental therapeutics
William A. Weiss, University of California, San Francisco, CA

Immune Regulation in the Tumor Microenvironment

Regulation of T cell homing to tumors
George Coukos, University of Pennsylvania Medical Center, Philadelphia, PA

Immune destruction of the tumor microenvironment
Hans Schreiber, University of Chicago, Chicago, IL

Th17 cells in the tumor microenvironment
Weiping Zou, University of Michigan School of Medicine, Ann Arbor, MI

Immune regulation from within the solid tumor microenvironment
Thomas F. Gajewski

Molecular Biomarkers of Response and Toxicity

Molecular biomarkers for prediction of toxicity
Mark J. Ratain, University of Chicago, Chicago, IL

Biomarker lessons learned from the development of HER family targeted agents
Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN

Challenges toward more relevant biomarkers
Joseph P. Eder, AstraZeneca LP, Waltham, MA

The future of molecular imaging as a predictive biomarker of response
Anthony F. Shields, Barbara Ann Karmanos Cancer Institute, Detroit, MI

Ruth Sager Memorial Symposium on Cancer Genetics and Epigenetics
Epigenomics and the Stem Cell: The Cancer Connection

Epigenetic regulation of stem cells and cancer
Bradley E. Bernstein, Massachusetts General Hospital, Charlestown, MA

DNA hypermethylation and gene silencing: Clues to the stem cell programming of cancer cells
Stephen B. Baylin, Johns Hopkins University School of Medicine, Baltimore, MD

Epigenetics in cancer: Cause and consequence
Paula M. Vertino, Emory University Winship Cancer Institute, Atlanta, GA

Epigenetic therapies
Peter A. Jones

Advances in Cancer Stem Cells: The Bayard D. Clarkson Symposium on Stem Cells and Cancer

Evolving concepts of cancer stem cells in cancer biology
Jeremy N. Rich

What can we learn about self renewal and drug resistance from the isolation of epithelial tumor stem cells?
Michael F. Clarke, Stanford University School of Medicine, Palo Alto, CA

Functional properties of human melanoma stem cells
Markus H. Frank, Children’s Hospital Boston, Boston, MA

Contribution of the vascular niche to the maintenance of cancer stem cells
Shahin Rafii, Cornell University Medical College, New York, NY

Cancer Metabolism: Back to the Future

Regulation of cancer cell survival under metabolic stress
Tak W. Mak

Dual control of caspase-2 by metabolism and the cell cycle machinery
Sally A. Kornbluth, Duke University Medical Center, Durham, NC

The role of myc in cancer metabolism and tumorigenesis
Chi Van Dang, Johns Hopkins University School of Medicine, Baltimore, MD

Cancer cell addiction to glutamine
Craig B. Thompson, University of Pennsylvania, Philadelphia, PA

Cell Cycle and Senescence in Cancer

Regulation of mitosis by protein phosphorylation and degradation
Marcos Malumbres, Spanish National Cancer Research Center, Madrid, Spain

Functional regulation of the Cdk inhibitor p27: Both loss and gain of function promote cancer progression
Joyce M. Slingerland, University of Miami Miller School of Medicine, Miami, FL

The senescence-associated secretory phenotype
Judith Campisi, Buck Institute for Age Research, Novato, CA

Functions of p53 in cell senescence and survival
Karen H. Vousden

Genome-Wide Association Studies in Cancer: Current and Future Directions

Introduction: GWAS and its trends
John D. Carpten

Discovery of new loci in less common cancers
Richard Houlston, Institute of Cancer Research, Sutton, United Kingdom

GWAS in different populations
Christopher A. Haiman, Zilkha Neurogenetic Institute, Los Angeles, CA

Discovery of new loci in GWAS in common cancers
Stephen J. Chanock

GWAS and risk assessment
Peter Kraft, Harvard School of Public Health, Boston, MA

Imaging Cancer Invasion: Metastasis and Resistance

3-D tissue invasion: Lessons from leukocytes
Michael Sixt, Max-Planck-Institute of Biochemistry, Martinsried, Germany

Collective invasion and resistance niches
Peter Friedl

Intravasation and metastatic seeding
James P. Quigley, The Scripps Research Institute, La Jolla, CA

Real-time imaging of intratumoral cytotoxic immune responses
Philippe Bousso, Institut Pasteur, Paris, France

NF-κB in the Development and Maintenance of Cancer

Regulation of NF-κB by deubiquitinases
Vishva M. Dixit, Genentech, Inc., South San Francisco, CA

Critical role of NF-κB activation in normal plasma cells and in multiple myeloma
W. Michael Kuehl, National Naval Medical Center, Bethesda, MD

Re-educating tumor-associated macrophages by targeting NF-κB
Toby Lawrence, Barts and The London School of Medicine and Dentistry, London, United Kingdom

Mechanisms of constitutive NF-κB activation in lymphoma revealed by functional genomics and cancer gene resequencing
Louis M. Staudt

The Cancer Genome: Recent Advances

The molecular genetics of acute leukemia
James R. Downing

Mining and translating the cancer genome
Lynda Chin, Dana-Farber Cancer Institute, Boston, MA

Insights into pathogenesis achieved through genomic analysis of glioblastoma multiforme
Donald W. Parsons, Baylor College of Medicine, Houston, TX

Transforming the cancer genomics paradigm
Elaine Mardis, Washington University School of Medicine, St. Louis, MO

From Molecular Tumor Markers to Health Behaviors: Promises and Challenges of Cancer Survivorship

Multidisciplinary approaches to understanding acute and late effects of breast cancer therapy
Dawn Hershman, Columbia University, New York, NY

Let’s get moving: Physical activity and health among cancer patients
Melinda L. Irwin, Yale University, New Haven, CT

Nutrition and supplements for cancer patients: Facts and fiction
Cornelia M. Ulrich

Health, mind, and quality of life among cancer survivors
Paul B. Jacobsen, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Autophagy, Metabolic Stress, and Therapeutic Response

Tumor suppression by autophagy and therapeutic implications
Eileen P. White

Autophagy control by oncogene and tumor suppressor gene products
Guido Kroemer, Institut Gustave Roussy, Villejuif, France

Autophagy in the control of tumor cell death
Kevin M. Ryan, Beatson Institute for Cancer Research, Glasgow, United Kingdom

Autophagy cancer and cancer therapeutics: Fact or fiction
Beth Levine, UT Southwestern Medical Center, Dallas, TX

Cancer Therapeutics and Nanotechnology

Neovascular targeted lipid-coated nanogel cores as versatile drug carriers
Eric A. Murphy, Moores UCSD Cancer Center, La Jolla, CA

Toward next-generation nanoparticles for cancer diagnosis and therapy
Sangeeta N. Bhatia, Massachusetts Institute of Technology, Cambridge, MA

Self-assembled and RES-evading nanoparticles for cancer imaging and therapy
Shuming Nie, Emory University, Atlanta, GA

Multiplexed targeted nanoemulsions for cancer diagnosis and therapy
Samuel Wickline, Washington University School of Medicine, St. Louis, MO

Inflammation and Cancer: Mechanisms Regulating Pro-tumor Immunity

Pulmonary metastasis potentiated by CD4+ T lymphocytes and M2 macrophages
Lisa M. Coussens

A pro-tumor role for T lymphocytes during colon carcinogenesis
Drew M. Pardoll, The Sidney Kimmel Comprehensive Cancer Research Center at Johns Hopkins, Baltimore, MD

The immune response to sporadic immunogenic cancer
Thomas Blankenstein, Max-Delbrück Center for Molecular Medicine, Berlin, Germany

Nf1-dependent tumors require a microenvironment containing Nf1+/- and c-kit dependent bone marrow
D. Wade Clapp, Indiana University Cancer Center, Indianapolis, IN

K-ras: 40 Years from Discovery to Clinical Application

Investigating the mTOR pathway and rationally designed combination therapies in Ras-driven cancers
Karen Cichowski

Biology and therapy of K-ras initiated pancreatic cancer in mice
David A. Tuveson, CRUK Cambridge Research Institute, Cambridge, United Kingdom

Preclinical interrogation of mutant K-ras driven genetically engineered mouse models of oncology
Leisa Johnson, Genentech, Inc., South San Francisco, CA

Genetic predictors of RAS/MEK dependence
David B. Solit, Memorial Sloan-Kettering Cancer Center, New York, NY

Minorities in Cancer Research (MICR) Symposium: Epigenetic Response to Stress in Determining Health Disparities

Epigenetic regulation of drug resistant genes and response to cancer therapy among populations
Francis Ali-Osman

A mouse model of breast cancer reveals metabolic pathway gene expression changes and increased tumor growth are associated with chronic stress
Suzanne D. Conzen, University of Chicago, Chicago, IL

Stress-related biomarkers and their association with health disparities
Ronald Glaser, The Ohio State University, Columbus, OH

New Approaches to Risk Prediction

Overview: The critical role of risk prediction in cancer prevention
Ernest T. Hawk, UT M. D. Anderson Cancer Center, Houston, TX

Nomograms for prediction of indolent prostate cancer
Michael W. Kattan, The Cleveland Clinic, Cleveland, OH

The value for clinical and public health decisions of adding SNPs to a model to project breast cancer risk
Mitchell H. Gail, National Cancer Institute, Bethesda, MD

Integrating epidemiologic and genetic data for lung cancer risk prediction
Margaret R. Spitz

Genome-wide association studies for risk prediction
Paul D. P. Pharoah, University of Cambridge, Cambridge, United Kingdom

New Kinase Targets in Cancer

Discovery and development of small molecule inhibitors of mTORC1 and mTORC2 as potential anticancer agents
Kevan M. Shokat, University of California, San Francisco, CA

The role of a novel PI3K effector, PKN3, in mediating normal and tumor cell signaling
Anke Klippel, Wyeth Pharmaceuticals, Pearl River, NY

Modeling sensitivity and resistance to kinase inhibitors in tumor-derived cell lines
Jeffrey Settleman, Massachusetts General Hospital Cancer Center, Charlestown, MA

Characterization of new candidate cancer-causing kinases emerging from cancer kinome sequencing
Tony Hunter

Targeted Agents Combined with Radiation

Radiosensitization by DNA repair inhibitors
Robert G. Bristow, Princess Margaret Hospital, Toronto, ON, Canada

EGFR inhibitors as sensitizers of chemoradiation
Mukesh K. Nyati, University of Michigan, Ann Arbor, MI

Histone deacetylase inhibitors combined with radiation in the treatment of high grade gliomas
Kevin A. Camphausen, National Cancer Institute, Bethesda, MD

Targeting the proteasome for radiosensitization
William H. McBride, University of California, Los Angeles, CA

Molecular Imaging of Cancer Pathways

Dynamic molecular imaging of signal transduction pathways in cancer
David Piwnica-Worms

Combinational vascular targeting and molecular imaging in cancer and obesity
Renata Pasqualini, UT M. D. Anderson Cancer Center, Houston, TX

Image guidance for advancing targeted biotherapies
Christopher H. Contag, Stanford University School of Medicine, Stanford, CA

Molecular imaging of androgen receptor blockade in castrate resistant prostate cancer
Steven M. Larson, Memorial Sloan-Kettering Cancer Center, New York, NY

Natural Products and Molecular Targeted Therapeutics

Microbial natural products, derivatives, and mimics as antitumor agents
David Newman, National Cancer Institute, Frederick, MD

Designed paclitaxels and epothilones as anticancer drug leads
David G. Kingston, Virginia Polytechnic Institute and State University, Blacksburg, VA

Toward a systematized approach of applying the information-rich content of natural products to chemical genetics
Daniel Romo, Texas A&M University, College Station, TX

Old drugs for new targets: A case study with novobiocin
Brian S. J. Blagg, University of Kansas, Lawrence, KS

Pathways to Lung Cancer: Untangling the Roles of Genes and Tobacco

Genetics of nicotine dependence and smoking behaviors: The smoke clears
Laura J. Bierut, Washington University School of Medicine, St. Louis, MO

Variation in nicotinic acetylcholine receptor genes CHRNA3 and CHRNA5 influences both smoking behavior and lung cancer risk: Characterization of risk in multiethnic populations
Christopher I. Amos, UT M. D. Anderson Cancer Center, Houston, TX

Lung cancer, smoking, and genetic susceptibility in African Americans
Ann G. Schwartz

Post genome-wide association research: Lessons from lung cancer studies
Paul J. Brennan, International Agency for Research on Cancer, Lyon, France

PI3K: Oncoprotein and Drug Targets

A new class of selective inhibitors of the p110-alpha isoform of PI3K as cancer drugs
William A. Denny, University of Auckland, Auckland, New Zealand

CAL-101, a specific PI3K p110δ inhibitor for the treatment of hematological malignancies
Niell A. Giese, Calistoga Pharmaceuticals, Seattle, WA

Novel small molecule inhibitors targeting the mTOR complex in cancer
Christian Rommel, Intellikine, Inc., La Jolla, CA

Therapeutics targeting the PI3K pathway
Carlos Garcia-Echevevia, Novartis Pharma, Inc., Basel, Switzerland

Targeting the Hypoxia Response in Tumors: Metabolic Implications

Evaluating the link between AMP kinase, glycolysis, and tumor growth
Nicholas C. Denko, Stanford University School of Medicine, Stanford, CA

Targeting cancer metabolism at the crossroads of the oncogene, MYC, and hypoxia regulated transcription factor, HIF-1
Chi Van Dang, Johns Hopkins University School of Medicine, Baltimore, MD

Tumor cell resistance to hypoxic and acidic stresses: Key roles of HIF-induced BNIPs, carbonic anhydrases, and MCTs
Jacques Pouyssegur, CNRS Institute of Developmental Biology and Cancer Research, Nice, France

Role of lactate as a fuel in a unique microenvironmentally controlled metabolic symbiont
Pierre Sonveaux, University of Louvain Medical School, Brussels, Belgium

The Stanley J. Korsmeyer Memorial Symposium: Controlling Cancer Programmed Cell Death

Targeting BCL-2 family control of apoptosis in cancer
Anthony G. Letai

Developing chemotherapeutics that target mitochondria
Craig B. Thompson, University of Pennsylvania, Philadelphia, PA

Cytosolic p53-Bcl-2 family interactions: Biological insights from structural studies
Douglas R. Green, St. Jude Children’s Research Hospital, Memphis, TN

Oncogenes, tumor suppressors, and cell death: The good, the bad, and the ugly
Gerard I. Evan, University of California Comprehensive Cancer Center, San Francisco, CA

The Successes and Challenges of Cell-Based Immunotherapies

HPV vaccination: Current realities and future prospects
Douglas R. Lowy, National Cancer Institute, Bethesda, MD

Cellular vaccines for pancreatic cancer
Elizabeth M. Jaffee

Effective cell transfer therapy for patients with metastatic melanoma
Steven A. Rosenberg, National Cancer Institute, Bethesda, MD

Utilizing marrow infiltrating lymphocytes for adaptive T cell therapy
Ivan Borrello, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

Apoptosis-Based Strategies for Cancer Therapy

Targeting cancer with proapoptotic receptor agonists
Avi Ashkenazi, Genentech, Inc., South San Francisco, CA

Targeting inhibitors of apoptosis signaling pathways
Philip A. Barker, McGill University, Montreal, QC, Canada

New applications of synthetic triterpenoids in cancer therapy
Karen T. Liby, Dartmouth Medical School, Hanover, NH

Blasting Bcl-2: More than one way to skin a cat
John C. Reed

Biomarkers in Epidemiology: Risk and Prognosis

Biomarkers of hepatocellular cancer risk
Regina M. Santella, Columbia University Mailman School of Public Health, New York, NY

Tissue biomarkers in epidemiology: Applications to studies of diet and cancer prevention
Johanna W. Lampe, Fred Hutchinson Cancer Research Center, Seattle, WA

Integrating biomarkers, epidemiology, and clinic
Paolo Boffetta

Biomarkers of response to therapy
Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

Infectious Etiologies: The Two-Sided Coin in Cancer

Helicobacter infection and gastric cancer: Multiple roles for bone marrow-derived cells
Timothy C. Wang, Columbia University Medical Center, New York, NY

Helicobacter pylori: A microbe that protects against adenocarcinoma of the esophagus
Martin J. Blaser, New York University School of Medicine, New York, NY

Viral hepatocarcinogenesis: Two routes to a common destination
Raymond T. Chung, Massachusetts General Hospital, Boston, MA

Beneficial microbes: Strategies for inflammation and cancer
James Versalovic, Baylor College of Medicine, Houston, TX

Noncoding RNAs

A noncoding RNA revolution in the cancer society
George A. Calin, UT M. D. Anderson Cancer Center, Houston, TX

Transcriptional and post-transcriptional mechanisms of miRNA reprogramming in normal cells and cancer cells
Joshua Mendell, Johns Hopkins University, Baltimore, MD

Noncoding RNA regulators of RNA polymerase II
Jennifer Kugel, University of Colorado, Boulder, CO

New insights on the regulatory capabilities of short RNAs
Isidore Rigoutsos

Telomere Maintenance and Cancer

Telomerase in stem cell regulation and cancer
Steven E. Artandi, Stanford University School of Medicine, Stanford, CA

Generating a functional map of the surface of telomerase
Alison A. Bertuch, Texas Children’s Hospital, Houston, TX

Short telomeres, pulmonary fibrosis, and stem cell failure in the lung
Mary Armanios, Johns Hopkins University School of Medicine, Baltimore, MD

Alternative lengthening of telomeres in human cancer
Roger R. Reddel, Children’s Medical Research Institute, Westmead, Australia

The Chemical Biology of Mutagenesis and DNA Repair

Interrogation, recognition, and repair of damaged bases in DNA
Gregory L. Verdine, Harvard University, Cambridge, MA

The MutY and MUTYH glycosylases: From damage recognition and repair to MAP
Sheila S. David, University of California, Davis, CA

Reading chemical and biological information: How errors arise in the recognition of genetic sequence
Eric T. Kool, Stanford University, Stanford, CA

The study of direct DNA demethylation repair
Chuan He, University of Chicago, Chicago, IL